On May 2, 2024, Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced the pricing of the underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $46 per share. The gross proceeds of the public offering are expected to be approximately $138 million, before deducting underwriting discounts and commissions and other estimated offering expenses. Soleno has also granted the underwriters a 30-day option to purchase up to 450,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The public offering is expected to close on or about May 7, 2024. Wilson Sonsini Goodrich & Rosati advised Soleno Therapeutics on the offering.

Soleno intends to use the net proceeds from this offering to fund its current research and development efforts primarily focused on advancing its lead candidate, DCCR tablets for the treatment of Prader-Willi Syndrome (PWS), and to provide for general corporate purposes, which may include working capital, capital expenditures, other clinical trials, other corporate expenses, and acquisitions of complementary products, technologies, or businesses, though the company does not have agreements or commitments for any specific acquisitions at this time.

The Wilson Sonsini team that represented Soleno Therapeutics in the transaction was led by Elton Satusky, Jesse Schumaker, and Davelyn Couch.

For more information, please see Soleno Therapeutics’ press release.